Abstract
Objective This study was investigated to determine whether CMBs were associated with the risk of recurrent stroke or all-cause death in patients with acute posterior circulation cerebral infarction.
Methods A retrospective analysis was conducted on 323 patients with acute posterior circulation cerebral infarction who aged ≥ 45 years and were hospitalized at Qingdao University Affiliated Hospital from January 1, 2016 to December 31, 2020. Patients were divided into different CMBs groups according to the presence, number and distribution of CMBs. Occurrence of stroke and death was recorded during follow-up. We drew Kaplan Meier survival curves and constructed Cox proportional hazards regression models based on different CMBs groups and clinical outcomes.
Results A total of 323 patients were enrolled in our study, and 138 (42.72%) had CMBs. During a median follow-up of 1357 days, 87 (26.94%) experienced recurrent stroke or death. ≥5 CMBs (HR 1.723; 95% CI 1.021-2.907; P=0.041) and lobar CMBs (HR 2.312; 95% CI 1.204-4.441; P=0.012) were independent predictors associated with the composite risk of recurrent stroke and all-cause death. All CMBs statuses were not significantly correlated with the risk of recurrent stroke. The presence of CMBs (HR 3.358; 95% CI 1.259-8.954; P=0.015), ≥ 5 CMBs (HR 5.290; 95% CI 1.599-17.499; P=0.006) and deep CMBs (HR 3.265; 95% CI 1.003-10.628; P=0.049) were all independent factors associated with all-cause death.
Conclusions In patients with acute posterior circulation cerebral infarction, ≥5 CMBs and lobar CMBs may increase the risk of poor clinical outcome (the composite of recurrent stroke and all-cause death). Furthermore, the presence CMBs, ≥ 5 CMBs and deep CMBs all independently may increase the risk of all-cause death.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by the Affiliated Hospital of Qingdao University (QDFY) grants (X2021010) and Qingdao University of Science and Technology (QUST) grants (WST 2021020).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The ethics committee of the Affiliated Hospital of Qingdao University approved this study (NO. QYFYWZLL27329).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data availability statement
All datesets are available free upon request to Prof Xueping Zheng. (simplexueping{at}qdu.edu.cn).
